Anonymous ID: b9297b Feb. 4, 2022, 3:04 a.m. No.15542508   🗄️.is 🔗kun   >>2522 >>2528 >>2555 >>2599 >>2606

>>15542057 FOIA reading room search term = Kindler (former Pfizer CEO - now head of Blackstone)

Email From Sid Blumenthal to H re:an article written by Blumenthal's son outlining Pharma, PHRMA and hussein's efforts during negotiations on obamacare. Actually a really good dig on big pharma's role (including Pfizer) and how they get to legislators.

Big Pharma successfully included language that Medicare could not negotiate drug prices.

Went to USA spending.gov to find out if the PHRMA gravy train was still rolling.

Turns out that Georgetown University is also involved…PHRMA created a collaborative effort at Georgetown University.

From 2015: "In addition to regular meetings with her mentors from Georgetown and industry partner Biogen…."

 

There are so many leads in the Blumenthal article that are relevant to today…

 

Blumenthal HuffPo article archived: https://archive.ph/7NPRN

Blumenthal HuffPo article direct link: https://www.huffpost.com/entry/the-legacy-of-billy-tauzi_b_460358

https://foia.state.gov/search/Results.aspx?searchText=%22Kindler%22&beginDate=&endDate=&publishedBeginDate=&publishedEndDate=&caseNumber=

Georgetown fellowship archive: https://archive.ph/lIltv

Anonymous ID: b9297b Feb. 4, 2022, 3:09 a.m. No.15542522   🗄️.is 🔗kun   >>2555 >>2569 >>2606

>>15542508 (me)

Last year, the Georgetown University Program for Regulatory Science & Medicine (PRSM) joined forces with the Pharmaceutical Research and Manufacturers of America (PhRMA) to create a postgraduate Fellowship in Regulatory Science. The fellowship provides a mentored research experience to guide the next generation of scientists. While the U.S. Food and Drug Administration (FDA) and other organizations offer fellowships in this area, the PRSM-PhRMA program is unique in that it brings together academia, industry and government in one collaborative training package.

 

Regulatory science—not to be confused with regulatory affairs—is important for the biopharmaceutical field as it draws on evidence-based scientific knowledge to inform decision-making about the safety and benefits of medical products to improve public health. For example, researchers in this emerging, interdisciplinary field may investigate molecular markers in patients with a rare disease to aid in therapeutic discovery and development.

Anonymous ID: b9297b Feb. 4, 2022, 3:32 a.m. No.15542569   🗄️.is 🔗kun   >>2606

>>15542522 (me) The echo chamber continues to be funded by the USG. From the Georgetown/PhRMA article:

Our first and current PRSM-PhRMA Regulatory Science fellow, Shahla Riazi, MD, Ph.D., has been working with a mentor from our FDA-supported Center of Excellence in Regulatory Science and Innovation (CERSI), on a research effort that marries clinical immunology understanding with biomedical informatics techniques to determine the predictive effect of biomarkers on therapeutic outcomes…

 

CERSI in the usaspending.gov database - $28 Million dollars. So CERSI participants are beholden to the FDA. Wonder if that colors their 'perceptions'?

 

https://www.usaspending.gov/keyword_search/%22CERSI%22

Anonymous ID: b9297b Feb. 4, 2022, 3:45 a.m. No.15542599   🗄️.is 🔗kun   >>2606 >>2644

>>15542508

One moar from the FOIA reading room on Kindler…. Talking w/HRC. Bonus find! Edgar Bronfman had HRC's cell phone number. kek! ooops. (alternative: Honk!)

 

https://foia.state.gov/search/Results.aspx?searchText=%22Kindler%22&beginDate=&endDate=&publishedBeginDate=&publishedEndDate=&caseNumber=